TARTARIC ACID, DL-

SMILES

Mwt.	LogP	HBD	HBA	PSA	RB	CSP3
148.0	-4.8	2	6	121.0	3	0.5

CAS

133379

UNII

4J4Z8788N8

SYNONYMS

ZINC ID(s)

Availability

Present in 114 ZINC catalogs

This compound has been observed to have activity at 10μM or less against the following gene(s).

Name	Description	Classification
GBA	Glucosylceramidase	Enzyme / Enzyme-Other

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).

Code	Date	Title	Phase	Status
NCT02023866	2014-06-01	Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease	Phase 2/Phase 3	Recruiting
NCT01749982	2012-12-01	A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh	Phase 4	Completed
NCT01529268	2012-06-01	Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children	Phase 2/Phase 3	Active, Not Recruiting
NCT01197378	2010-08-01	Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)	Phase 3	Active, Not Recruiting
NCT01149538	2010-07-01	Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure	Phase 1/Phase 2	Completed
NCT01000961	2010-06-01	Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis	Phase 3	Completed
NCT02170896	2001-10-01	Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects	Phase 1	Completed

Browse on ZINC

Data provided by OpenFDA